Atopic dermatitis is a chronic inflammatory skin condition with episodes of egzacerbation and remission. It is characterized by the involvment of skin barrier defects, innate immune response, colonization of the skin with microorganisms and frequent skin infections. In 1980. Hanifin and Rajka suggested diagnostic criteria based on the minor and major features of the clinical presentation which was revisited in 2014. when a simplified version was suggested as the new diagnostic criteria. There are three stages of atopic dermatitis – the infantile stage, the childhood stage and the adult stage, and the condition most often first appears during infancy. In the infantile stage the lesions affect the face and the scalp, extensor surfaces of the extremities while the diaper area is spared. In the childhood stage lesions appear on the wrists, ankles, hands and feet and elbow and knee flexures, while in the adult stage they mostly appear on the flexor surfaces of the extremities, the face and the neck and the distal extremities. Pruritus and xerosis are two characteristics that appear in all three stages. Pruritus can be present during the day but it is more intense during the night which often leads to trouble with sleeping and other problems with psychosocial functioning. About 80% of all patients will develop allergic rhinitis or asthma, and with the development of these conditions, the symptoms of atopic dermatitis sometimes improve. „Atopic march“ is a term developed to describe the progress of atopic dermatitis to allergic rhinitis and asthma. Mild atopic dermatitis is treated primarly with local corticosteroids in the periods of egzacerbation, or sometimes other local medication. Moderate atopic dermatitis is alongside local corticosteroids also treated with phototherapy. Severe forms of atopic dermatitis require systematic imunosupressors. Dupilumab is a new biologic medication which is currently the only one registered for the treatment of severe forms of atopic dermatitis.